Evocalcet
As of the edition of 20 October 2026, Evocalcet is a small molecule: marketed, first approved in 2018 (JP); acts on CASR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Orkedia
- First approved
- 23 March 2018 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Kyowa Hakko Kirin Co., Ltd.; 2 holders in all
- Registered trials
- 9, 0 stopped early
- Disease areas
- Hormones; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Evocalcet.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CASR | Extracellular calcium-sensing receptor | P41180 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 5 | 5 | 0 | 0 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Kyowa Kirin | Applicant and Lead sponsor of trials | 2013 to now |